Company Overview
| Company Name |
TAXUS PHARMACEUTICALS, INC. |
| Company Address |
ROOM 1202, 12TH FLOOR
JIN SHANG INTERNATIONAL GOLDEN TOWER
JINZHONG 030600 |
| Company Phone |
863543366761 |
| Company Website |
-- |
| CEO |
Jiayue Zhang |
| Employees (as of 6/25/2012) |
84 |
| State of Inc |
NV |
| Fiscal Year End |
12/31 |
| Status |
Filed (7/3/2012) |
| Proposed Symbol |
-- |
| Exchange |
OTCBB |
| Share Price |
$0.25 |
| Shares Offered |
862,000 |
| Offer Amount |
$215,500.00 |
| Total Expenses |
$200,024.70 |
| Shares Over Alloted |
-- |
| Shareholder Shares Offered |
862,000 |
| Shares Outstanding |
22,642,500 |
| Lockup Period (days) |
180 |
| Lockup Expiration |
-- |
| Quiet Period Expiration |
-- |
| CIK |
0001549065 |
We will not receive any of the proceeds from the sale of Shares by the Selling
Stockholders.
There are multiple companies in China that are also growing Yew trees for
purpose of extracting Paclitaxel. The significant ones are:
Chengdu Taxus Media Resources Development Co. Ltd.
Jiangsu Yew Biotechnology Co., Ltd.
Sichuan Jinhe Yew Agricultural Science and Technology Co., Ltd.
Shanxi New Taxus Media Planting Co., Ltd.
Hongdou Group-Jiangsu Hongdou Enterprise Shares Company, Ltd (Chinese listed
company, stock symbol 600400)
There are a number of Companies in China that have been extracting and
producing Paclitaxel and related products. The significant ones are:
Chengdu Li Er Pharmaceutical Co., Ltd.
The Hainan Yew Park Pharmaceutical Co., Ltd.
The Chongqing Meilian Pharmaceutical Co., Ltd.
Sichuan Jiufeng natural pharmaceutical Co., LTD
Beijing Concord Pharmaceuticals
As to the retail pharmacy business, there are a large number of pharmacy
companies in China and the market competition is intense. The number of
branches stores we have, the size of our stores and the sales we generated
each year decided that we are only a small local retail pharmacy chain
operator. Since we are located in Jinzhong, Shanxi Province, China, our
major local competitors are:
Great wall Chain pharmacy, now has 16 pharmacies opened at Taiyuan, Yuci ,
Jinzhong, and surrounding countries. Their annual sales are approximately
$ 4,500,000.
Jinzhong Baohetang Pharmaceutical Co., Ltd now has 10 pharmacies in Jinzhong
and their annual sales are approximately between $ 1,200,000 and
$ 1,500,000.
As to the dietary supplement product, similar to our retail pharmacy business,
it also faces intense competition in China and given the size of our
operations, we are only a small scale and local manufacturer of dietary
supplements. Our major competitors in the market include:
Dongying Jialekang Biological Engineering Co., Ltd.
Shanghai Taiyun Technology Co., Ltd
Tibet Yage (Fujian) Biotechnology Co., Ltd
Fuhai Jiaotai Biotechnology Company
Company Description
Taxus Pharmaceuticals, Inc. was founded under the laws of the State of
Nevada on February 17, 2012. On March 28, 2012, we completed a share exchange
transaction with China Sequoia, the sole shareholder of Stand Giant, under
which we issued 13,244,500 shares of common stock to China Sequoia in
exchange for the total issued and outstanding shares of Stand Giant. Prior
to the exchange, Shing Ming Wong, the sole shareholder of China Sequoia,
was China Sequoia's director till April 17, 2012. Jiayue Zhang, the director
of Taxus Pharmaceuticals, became the director of China Sequoia on April 17,
2012 after the share exchange between Taxus Pharmaceuticals and China Sequoia
was completed on March 28, 2012.
Upon the completion of the share exchange transaction, Stand Giant became our
wholly owned subsidiary and we began to engage in the business of growing Yew
trees, selling Yew tree bonsai, researching and developing paclitaxel (extract
from Yew), retail pharmacy and health care product manufacturing and
developing in China through Stand Giant's wholly owned Chinese subsidiary
Hongshan Energy and its variable interest entities Hongshan Pharmaceuticals
and Renji Pharmaceuticals.
Hongshan Pharmaceuticals and Renji Pharmaceuticals became the variable
interest entities ("VIE") (as defined in ASC 810-10, formally FIN 46(R))
of Hongshan Energy on June 28, 2011 through a series of contractual
arrangements. The contractual arrangements include an Exclusive Consulting
Agreement, a Share Pledge Agreement and a Call Option Agreement. Under the
Exclusive Consulting Agreement, Hongshan Energy provided consulting services
to Hongshan Pharmaceuticals and Renji Pharmaceuticals in areas of financing,
management, marketing and public relations. Hongshan Energy's compensation
for the services provided under the Consulting Service Agreement is the
post-tax net earnings of Hongshan Pharmaceuticals and Renji, which also
subject Hongshan Energy to the risk of assuming the loss of Hongshan
Pharmaceuticals and Renji Pharmaceuticals in the event that Hongshan
Pharmaceuticals and Renji Pharmaceuticals suffer net loss in any fiscal
year. Additionally, under a Call Option Agreement, the shareholders of
Hongshan Pharmaceuticals and Renji Pharmaceuticals have vested their voting
rights over Hongshan Pharmaceuticals and Renji Pharmaceuticals to Hongshan
Energy. In order to further reinforce Hongshan Energy's rights, Hongshan
Pharmaceuticals and Renji Pharmaceuticals and their shareholders have granted
Hongshan Energy, under the Call Option Agreement, the exclusive right and
option to acquire all of their equity interests in Hongshan Pharmaceuticals
and Renji Pharmaceuticals. Further, the shareholders of Hongshan
Pharmaceuticals and Renji Pharmaceuticals pledged all of their rights,
titles and interests in Hongshan Pharmaceuticals and Renji Pharmaceuticals
to Hongshan Energy under the Share Pledge Agreement. The shareholders of
Hongshan Pharmaceuticals and Renji Pharmaceuticals also granted power of
attorney to Hongshan Energy to exercise all the shareholder's rights and
shareholder's voting rights.
--------
Our principal office is located at 12th Floor, Room 1202 , Jinshang
International Golden Tower, Yuci District, Jinzhong City, Shanxi Province,
China 030600. Our telephone number is 011-86-354-3366667.
There are no news stories for this IPO at this time.